Other
Neoplasm by Cause
CI-CAN-00000032Explore in graph →
Non-malignant195 active trials4 approved drugs1 evidence items
- NCIt
- C27933
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000032Explore in graph →
Clinical trials
708 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05583149 | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | active not recruiting | Phase 2 | 28 | Patrick C. Johnson, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05846724 |
| Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) |
| withdrawn |
| Phase 2 |
| 0 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER |
| 0 |
| Jan 22, 2026 |
| clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03077451 | Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 36 | AIDS Malignancy ConsortiumNETWORK | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06756269 | To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | recruiting | Phase 2 | 330 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02588651 | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | completed | Phase 2 | 23 | Deepa JagadeeshOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04180215 | A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers | completed | Phase 1 / Phase 2 | 198 | Hookipa Biotech GmbHINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)(5) | terminated | Phase 2 | 10 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159620 | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients | recruiting | Phase 2 | 27 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas(NAVAL-1) | terminated | Phase 2 | 102 | Viracta Therapeutics, Inc.INDUSTRY | 14 | Jul 28, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03944915 | De-Escalation Therapy for Human Papillomavirus Negative Disease(DEPEND) | completed | Phase 2 | 35 | University of ChicagoOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03107182 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer(OPTIMA-II) | completed | Phase 2 | 72 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT02631746 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT04102150 | Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma | completed | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT02532231 | Nivolumab in AML in Remission at High Risk for Relapse | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT02029430 | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | completed | Phase 2 | 15 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05411107 | Oral Iloprost for the Prevention of Lung Cancer In Former Smokers | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT03993106 | A Study of sEphB4-HSA in Kaposi Sarcoma | unknown | Phase 2 | 65 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | completed | Phase 2 | 71 | Kyowa Kirin, Inc.INDUSTRY | 6 | Apr 25, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03961919 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant(FLAT-Auto) | completed | Phase 2 | 15 | Ciceri FabioOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00924170 | Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 29, 2026source: clinicaltrials